Last reviewed · How we verify
Gefitinib, raltitrexed
Tyrosine kinase inhibitor
Tyrosine kinase inhibitor Used for Non-small cell lung cancer.
At a glance
| Generic name | Gefitinib, raltitrexed |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Tyrosine kinase inhibitor |
| Target | EGFR |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Gefitinib is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR).
Approved indications
- Non-small cell lung cancer
Common side effects
- Diarrhea
- Nausea
- Vomiting
Key clinical trials
- A Phase 2 Study of Tomudex & Iressa as Second Line Chemotherapy in Subjects With Colorectal Carcinoma (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gefitinib, raltitrexed CI brief — competitive landscape report
- Gefitinib, raltitrexed updates RSS · CI watch RSS
- AstraZeneca portfolio CI